GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Other Gross PPE

Patrys (ASX:PAB) Other Gross PPE : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Patrys Other Gross PPE?

Patrys's Other Gross PPE for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Patrys Other Gross PPE Historical Data

The historical data trend for Patrys's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Patrys Other Gross PPE Chart

Patrys Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Patrys Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Patrys Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Patrys Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

Patrys Headlines